4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate profile

ID Source	ID
PubMed CID	9843897
CHEMBL ID	1231506
CHEMBL ID	106227
SCHEMBL ID	3685373
MeSH ID	M0445292

Synonym
CHEMBL1231506
teglicar
(3r)-3-{[(tetradecylamino)carbonyl]amino}-4-(trimethylammonio)butanoate
teglicar [inn]
bdbm50122839
chembl106227
[3-carboxy-2-(3-tetradecyl-ureido)-propyl]-trimethyl-ammonium
unii-8v3vq6hmii
4-trimethylammonio-tdcab
(3r)-3-((tetradecylaminocarbonyl)amino)-4-(trimethylazaniumyl)butanoate
250694-07-6
8v3vq6hmii ,
SCHEMBL3685373
AKOS027323786
st1326
st1326, (r)-3-(3-tetradecylureido)-4-(trimethylammonio)butanoate, powder
(3r)-3-[(tetradecylcarbamoyl)amino]-4-(trimethylammonio)butanoate
st1326; (r)-n-tetradecylcarbamoyl-aminocarnitine
HY-16482
(3r)-3-(tetradecylcarbamoylamino)-4-(trimethylazaniumyl)butanoate
(r)-3-(3-tetradecylureido)-4-(trimethylammonio)butanoate
CS-0006357
Q27271060
MS-26779

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carnitine O-palmitoyltransferase 2, mitochondrial	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.3800	0.3800	2.0933	5.1000	AID719698
Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)	IC50 (µMol)	0.1600	0.1600	2.0300	3.9000	AID719674
Carnitine O-palmitoyltransferase 1, liver isoform	Rattus norvegicus (Norway rat)	IC50 (µMol)	58.8000	0.0400	0.0650	0.0900	AID49183
Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)	IC50 (µMol)	1.0500	1.0500	1.0500	1.0500	AID719720
Carnitine O-palmitoyltransferase 1, muscle isoform	Rattus norvegicus (Norway rat)	IC50 (µMol)	56.4100	0.3800	2.0325	5.1000	AID49186; AID719675; AID719698
Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)	IC50 (µMol)	3.4250	0.1259	4.2440	10.0000	AID719675; AID719719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
long-chain fatty acid metabolic process	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
in utero embryonic development	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine shuttle	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine metabolic process	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
response to hypoxia	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
long-chain fatty acid metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
glucose metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
triglyceride metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
carnitine shuttle	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to nutrient	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to xenobiotic stimulus	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
carnitine metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
regulation of lipid storage	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to organic cyclic compound	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
epithelial cell differentiation	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
positive regulation of fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
eating behavior	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to alkaloid	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
positive regulation of innate immune response	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to ethanol	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
aflatoxin metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
regulation of insulin secretion	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
cellular response to fatty acid	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
liver regeneration	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to tetrachloromethane	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
fatty acid metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
fatty acid metabolic process	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
carnitine shuttle	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
carnitine metabolic process	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
response to blue light	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
long-chain fatty acid transport	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
carnitine O-palmitoyltransferase activity	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
protein binding	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine O-octanoyltransferase activity	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
acyltransferase activity	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine O-palmitoyltransferase activity	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
protein-macromolecule adaptor activity	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
identical protein binding	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
palmitoleoyltransferase activity	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
carnitine O-palmitoyltransferase activity	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
protein binding	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleoplasm	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
nucleolus	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
mitochondrial outer membrane	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
membrane	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
mitochondrial outer membrane	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay ID	Title	Year	Journal	Article
AID719683	Reduction in HOMA index in NIDD patient at 450 mg/day, po for 15 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719662	Inhibition of carnitine palmitoyltransferase in rat liver mitochondria assessed as conversion of [14C]palmitic acid to [14C]palmitoylcarnitine by radiometric assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719639	Reduction in glucose production in Sprague-Dawley rat at 5 to 25 pmol, icv administered as one or two single doses	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719644	Reduction in water consumption in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719641	Reduction in BHB level in po dosed 24 hrs fasted rat measured up to 12 hrs post dose	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719642	Increase in circulating FFA level in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719646	Reduction in liver glycogen level in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719672	Cytotoxicity in human KB cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719661	Inhibition of carnitine palmitoyltransferase in rat heart mitochondria assessed as conversion of [14C]palmitic acid to [14C]palmitoylcarnitine by radiometric assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID49186	In vitro inhibition of [14C]palmitoyl-CoA and carnitine binding to carnitine palmitoyltransferase I of rat heart mitochondria	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.
AID719698	Inhibition of rat CPT2	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719673	Inhibition of human FAO	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719682	Reduction in fasting insulin in NIDD patient at 450 mg/day, po for 15 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719671	Inhibition of rat FAO	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719715	Competitive inhibition of carnitine palmitoyltransferase using palmitoyl-CoA	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719637	Inhibition of ketogenesis in fasted po dosed cynomolgus monkey	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719635	Reduction in glucose level in db/db mouse at 80 mg/kgl/day, po for 12 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719640	Reduction in blood glucose level in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719719	Inhibition of human CPT1B	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719647	Reduction in serum glucose in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719645	Reduction in serum fructosamine level in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719643	Increase in liver TG level in db/db mouse at 50 mg/kg, po bid for 45 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719684	Half life in NIDD patient at 150 to 450 mg/day, po for 15 days	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719675	Maximal inhibition of rat CPT1A	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719720	Inhibition of human CPT1A	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID49183	Inhibition of [14C]palmitoyl-CoA and carnitine binding to carnitine palmitoyltransferase I from rat liver mitochondria	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.
AID719674	Inhibition of human CPT2	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719711	Critical micelle concentration of compound	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (37.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
betaine glycine betaine : The amino acid betaine derived from glycine.	2.03	1	amino-acid betaine; glycine derivative	fundamental metabolite
carnitine [no description available]	4.42	6	amino-acid betaine	human metabolite; mouse metabolite
4-hydroxyphenylglyoxylic acid 4-hydroxyphenylglyoxylic acid: RN given refers to parent cpd. 4-hydroxyphenylglyoxylate : Conjugate base of 4-hydroxyphenylglyoxylic acid.	2.06	1	phenols
2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid [no description available]	2.06	1
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.06	1	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	2.06	1	piperidines	cardiovascular drug
trimetazidine Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.	2.06	1	aromatic amine
4-hydroxyphenylglycine, (s)-isomer L-4-hydroxyphenylglycine : The L-enantiomer of 4-hydroxyphenylglycine.	2.06	1	4-hydroxyphenylglycine
ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate [no description available]	2.06	1
methyl 2-tetradecylglycidate methyl 2-tetradecylglycidate: structure	2.06	1
emeriamine emeriamine: derived from fungal metabolite emericedin; structure given in first source	2.45	2
nadp [no description available]	3.23	1
etomoxir [no description available]	2.06	1	aromatic ether
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source. (2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration.	2.06	1	4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid; gamma-lactone
b 807-27 [no description available]	2.06	1

Condition	Relationship Strength	Studies
Alloxan Diabetes [description not available]	2.01	1
Acetonemia [description not available]	2.01	1
Diabetes Mellitus, Adult-Onset [description not available]	2.47	2
Cardiac Failure [description not available]	2.06	1
Insulin Sensitivity [description not available]	2.47	2
Heart Disease, Ischemic [description not available]	2.06	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.47	2
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.06	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.47	2
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2.06	1
African Lymphoma [description not available]	2.08	1
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	2.08	1
Acute Myelogenous Leukemia [description not available]	2.11	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.11	1
Benign Neoplasms [description not available]	3.04	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.04	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.03	1

4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate

Cross-References

Synonyms (24)

Protein Targets (6)

Inhibition Measurements

Biological Processes (27)

Molecular Functions (7)

Ceullar Components (6)

Bioassays (28)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.47

Study Types

4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate

Cross-References

Synonyms (24)

Protein Targets (6)

Inhibition Measurements

Biological Processes (27)

Molecular Functions (7)

Ceullar Components (6)

Bioassays (28)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.47

Study Types

Related Drugs (15)

Related Conditions (17)